Health
Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies | Vaccines | News Channels – PipelineReview.com
La Merie Publishing prepares brief and full reports as well as competitor analysis reports, the latter in a tabulated format with structured listings of industry-relevant data. One of our top-selling.
Details
Category: Vaccines
Published on Thursday, 30 July 2020 13:24
Hits: 538
NEW BRUNSWICK, NJ, USA I July 30, 2020 I Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature, show the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by “neutral…
-
Noosa News23 hours agoAbusive bus driver fired by council loses appeal
-
General19 hours agoIran’s currency at record low as tensions run high
-
General23 hours agoTwo groups of men evicted from Rabbitohs and Roosters NRL clash after wild brawl
-
General18 hours agoLabor to pledge $2.3 billion to subsidise home batteries